spacer
home > epc > autumn 2003 > obstacles ahead for asthma vaccines
PUBLICATIONS
European Pharmaceutical Contractor

Obstacles Ahead for Asthma Vaccines

The immune system involves a balance between T helper cell Th1- and Th2-generated proteins called cytokines. Broadly speaking, in allergic individuals there is an over-stimulation of the Th2 response. A number of novel attempts aimed at restoring the Th1/Th2 balance are currently being investigated as possible cures for diseases such as allergic rhinitis and asthma. One such approach, Chiron's needle-free injection, Cat-PAD (peptide antigen desensitisation), is currently in Phase I. It consists of overlapping peptides containing T-cell specific allergen epitopes and MHC (major histocompatability complex)-binding sequences. Cat-PAD appears to offer significant advantages over traditional specific immune therapy. This is the only treatment known to halt the progression of allergic rhinitis, but because it involves the administration of specified quantities of allergen extracts over a three to five year period and because of serious safety concerns, immune therapy currently accounts for only two to four per cent of the US$9 billion allergy market.

The use of immune therapy is restricted to allergy specialists and is most frequently prescribed in Spain, Italy, France, Germany and the US. In contrast, despite possessing one of the highest prevalence rates of allergy in the world - with one in three people reporting allergy symptoms at some stage - immune therapy is rarely used in the UK. This is largely due to a dire lack of allergists and the severe prescribing restrictions imposed by the regulatory authorities following a 1986 British Medical Journal article citing 26 immune therapy induced fatalities over 30 years.

Cat-PAD has been erroneously labelled as an asthma vaccine and touted by the media as a potential means of removing the need for asthma inhalers in the future. In fact, it is more correctly labelled an allergy vaccine and a number of major obstacles must be overcome if it is to succeed, as illustrated in Figure 1.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Lisa Frawley, Respiratory Analyst at Datamonitor Healthcare

Lisa Frawley, PhD, is the Respiratory Analyst in the Immune Disorders and Inflammation group at Datamonitor Healthcare. She joined the company in September 2002 and has published a number of comprehensive reports in this area, involving analysis of pipeline therapies, physician treatment practices, inhaler devices and market dynamics. Prior to joining Datamonitor, Lisa studied Pharmacy at Trinity College Dublin, Ireland, where she practised as a Pharmacist in both retail and hospital settings, before commencing a PhD in Pharmacology at the University of Cambridge.

spacer
Lisa Frawley
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck to Provide BioReliance® End-to-End Solutions to Phanes Therapeutics

• Collaboration to accelerate development and manufacturing of Bispecific Antibody • Merck plans to offer Phanes a full suite of products and services under its BioReliance® offering
More info >>

White Papers

Blockbuster Drugs Need Blockbuster Components

West Pharmaceutical Services, Inc.

Many of the world’s blockbuster drugs are now delivered via a prefilled syringe system or auto-injector. To ensure patient safety, pharmaceutical manufacturers need high-quality components that feature reduced particulates and ensure consistency of delivery while fitting the changing needs of higher-volume delivery systems.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement